# OnCo record clovis-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/clovis-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "clovis-oncology" ;
  schema:name "Clovis Oncology"@en ;
  schema:alternateName "Clovis Oncology, Inc."@en ;
  schema:description "Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023."@en ;
  schema:url <https://onco.cc/companies/clovis-oncology/>, <https://www.clovisoncology.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Clovis_Oncology> ;
  owl:sameAs <http://www.wikidata.org/entity/Q23786068> ;
  schema:citation <https://clinicaltrials.gov/search?lead=Clovis%20Oncology>, <https://en.wikipedia.org/wiki/Clovis_Oncology> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/rucaparib/> ;
  onco:trials <https://onco.cc/trials/nct03899155/> .